Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Department of Macromolecular Structures, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Eur J Immunol. 2021 Nov;51(11):2633-2640. doi: 10.1002/eji.202149319. Epub 2021 Aug 19.
Here, we describe a new, simple, highly multiplexed serological test that generates a more complete picture of seroconversion than single antigen-based assays. Flow cytometry is used to detect multiple Ig isotypes binding to four SARS-CoV-2 antigens: the Spike glycoprotein, its RBD fragment (the main target for neutralizing antibodies), the nucleocapsid protein, and the main cysteine-like protease in a single reaction. Until now, most diagnostic serological tests measured antibodies to only one antigen and in some laboratory-confirmed patients no SARS-CoV-2-specific antibodies could be detected. Our data reveal that while most patients respond against all the viral antigens tested, others show a marked bias to make antibodies against either proteins exposed on the viral particle or those released after cellular infection. With this assay, it was possible to discriminate between patients and healthy controls with 100% confidence. Analysing the response of multiple Ig isotypes to the four antigens in combination may also help to establish a correlation with the severity degree of disease. A more detailed description of the immune responses of different patients to SARS-CoV-2 virus might provide insight into the wide array of clinical presentations of COVID-19.
在这里,我们描述了一种新的、简单的、高度多重的血清学检测方法,它比基于单一抗原的检测方法更能全面反映血清转化情况。该方法使用流式细胞术检测多种 Ig 同种型与四种 SARS-CoV-2 抗原结合:刺突糖蛋白、其 RBD 片段(中和抗体的主要靶标)、核衣壳蛋白和主要半胱氨酸蛋白酶。到目前为止,大多数诊断性血清学检测仅测量针对一种抗原的抗体,在一些实验室确诊的患者中,无法检测到 SARS-CoV-2 特异性抗体。我们的数据表明,虽然大多数患者对所有测试的病毒抗原都有反应,但其他患者对病毒颗粒表面暴露的蛋白或细胞感染后释放的蛋白产生抗体的倾向性明显更强。使用该检测方法,可以 100%置信度区分患者和健康对照者。分析针对四种抗原的多种 Ig 同种型的反应结合起来,也可能有助于确定与疾病严重程度的相关性。更详细地描述不同患者对 SARS-CoV-2 病毒的免疫反应,可能有助于深入了解 COVID-19 的广泛临床表现。